Illumina, Inc. $ILMN Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 4.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 310,751 shares of the life sciences company's stock after selling 13,928 shares during the quarter. Illumina comprises about 1.0% of Douglas Lane & Associates LLC's investment portfolio, making the stock its 28th biggest position. Douglas Lane & Associates LLC owned 0.21% of Illumina worth $85,046,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ILMN. Baker Tilly Wealth Management LLC boosted its position in Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company's stock valued at $355,000 after buying an additional 42 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in Illumina by 19.7% in the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company's stock valued at $80,000 after acquiring an additional 48 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Illumina by 1.5% during the third quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the life sciences company's stock worth $1,103,000 after purchasing an additional 61 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company's stock worth $348,000 after buying an additional 85 shares during the last quarter. Finally, Gabelli Funds LLC raised its position in shares of Illumina by 2.0% during the 1st quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company's stock valued at $616,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 2,061,850 shares of company stock worth $436,479,102 over the last 90 days. 2.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on ILMN. Citigroup lifted their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research report on Monday, August 3rd. Canaccord Genuity Group raised their target price on shares of Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a research note on Monday, August 3rd. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a "hold" rating in a report on Wednesday, August 5th. Finally, Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $222.19.

Illumina Trading Up 3.0%

ILMN traded up $8.06 during mid-day trading on Friday, reaching $272.63. The stock had a trading volume of 714,776 shares, compared to its average volume of 2,169,341. The firm's fifty day simple moving average is $225.72 and its two-hundred day simple moving average is $180.21. The stock has a market capitalization of $41.17 billion, a P/E ratio of 50.76, a P/E/G ratio of 3.79 and a beta of 1.41. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $309.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the prior year, the business earned $1.19 EPS. Illumina's revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.